Ferrous Lactate.

Ascorbic acid holds lactate-bound iron in the ferrous state and in solution through the duodenum. More of the dose then crosses the enterocyte.

Vitamin C counters phytate and polyphenol binding of non-heme iron in the same meal. It is the standard companion for a ferrous salt.

Calcium taken alongside iron lowers non-heme iron uptake. Splitting the two across the day keeps each intake usable.

Zinc and iron compete for DMT1 when both are dosed together at high amounts. Separate timing removes the competition.

Copper sits in the ferroxidases that load absorbed iron onto transferrin. Adequate copper is what turns absorbed iron into circulating iron.

Folate covers the DNA synthesis side of red cell production and iron the heme side. Both are required for output to keep pace.

B12 supports the same nucleotide synthesis step as folate in dividing marrow precursors. Iron then fills those cells with hemoglobin.

Flavins from riboflavin drive the reduction that releases ferritin iron for transport. Riboflavin status changes how far a given iron dose goes.

Vitamin A status affects release of stored iron into circulation. With adequate vitamin A, the same iron intake shows up more fully in blood.

Tea catechins bind non-heme iron in the lumen into complexes that are not taken up. Dosing them together lowers delivered iron.

Low gastric pH keeps ferrous lactate dissolved and unoxidised before it reaches the duodenum. Added acidity protects the absorbable fraction.

Phytase degrades phytate, the main binder of non-heme iron in plant meals. Iron uptake improves because the inhibitor is removed.

Lactobacilli lower luminal pH and generate lactate, which keeps iron in the more soluble ferrous form. The effect is strain-specific and modest.

Galloyl groups on tannins bind ferrous and ferric iron in the gut lumen and form complexes that are not taken up by the enterocyte. Tea, coffee and many polyphenol-rich extracts carry this chemistry. The effect is meal-bound, so separating the iron dose from the tannin source in time removes most of it.

Ferrous iron stays in solution in an acidic stomach and oxidises and precipitates as pH rises toward neutral. Anything that raises gastric pH, including bicarbonate and other antacids, lowers the soluble ferrous fraction available at the duodenal brush border. This is why iron salts are usually taken away from acid-neutralising agents.

Manganese and ferrous iron are both carried across the apical enterocyte membrane by DMT1, and the two compete for that transporter when given together. Iron status also alters DMT1 expression, so the competition is not symmetrical. Spacing the two doses is the usual response.

Pyridoxal-5-phosphate is the cofactor for delta-aminolevulinic acid synthase, the first and rate-limiting enzyme of heme synthesis, which is the step that condenses glycine with succinyl-CoA before iron is ever inserted. Supplying iron without adequate B6 leaves the pathway constrained upstream of the metal. This is settled pathway biochemistry rather than a combination trial.

Glycine is the amino acid substrate that ALA synthase condenses with succinyl-CoA at the start of heme synthesis, and it is also the ligand in amino acid chelated iron forms, where the chelate keeps iron soluble across a range of gut pH. Ferrous lactate is an organic salt rather than an amino acid chelate, so it does not carry that ligand itself. The pairing rests on both roles, neither of which has been tested against ferrous lactate specifically.

Colonic fermentation of inulin lowers luminal pH and produces short-chain fatty acids, and a more acidic colonic environment keeps a larger share of unabsorbed iron soluble. Some absorption does occur distal to the duodenum. The measured endpoints in this literature are usually iron status markers rather than clinical outcomes.

Galactooligosaccharides are fermented in the proximal colon and acidify the lumen in the same way inulin does, which affects the solubility of iron that escaped duodenal uptake. They also shift the microbial population that competes for luminal iron. The evidence sits at the level of markers, and no study has used ferrous lactate as the iron source.

The catechol group on quercetin chelates iron with high affinity, which is well characterised in laboratory work and is the basis of its metal-binding antioxidant behaviour. Taken in the same meal as an iron salt it lowers the soluble absorbable fraction. The interaction is dose and timing dependent.

Curcumin binds iron through its beta-diketone moiety, and this iron-binding behaviour is one of its better-characterised chemical properties. High-dose curcumin taken alongside an iron salt reduces the free iron pool in the lumen. Anyone taking both for a reason should separate them across the day.

Silybin and related flavonolignans carry phenolic hydroxyls that bind iron in laboratory systems. Whether that meaningfully changes absorption of an oral iron salt in people has not been established. It is flagged because the two are frequently taken by the same person.

The carboxyl groups on pectin's galacturonic acid backbone bind divalent cations including ferrous iron, and viscous fibre also slows the mixing that iron uptake depends on. The net effect on absorbed iron from a supplement dose is modest and depends on the fibre load. It is worth noting on a formula that combines an iron salt with a viscous fibre.

Lysine has been reported alongside oral iron in supplementation reports on ferritin response, and the proposed route is improved iron solubility and handling rather than a transporter effect. The work is small and does not use ferrous lactate. Ferritin is a status marker, not a clinical outcome.

Lactoferrin binds two ferric ions per molecule with very high affinity and delivers them by a route that does not depend on DMT1. Given with a ferrous salt it changes how much free iron sits in the lumen. Whether that helps or competes depends on dose and timing, which is why the polarity here is modulating rather than additive.

Unabsorbed ferrous iron can drive Fenton chemistry in the gut lumen and initiate lipid peroxidation. Alpha-tocopherol terminates the resulting lipid radical chain in the membrane phase. The pairing addresses a chemistry problem created by the iron dose itself rather than adding to iron delivery.

The dithiolane ring of lipoic acid and its reduced form bind transition metals including iron, which is part of how it behaves as a redox-active compound. That binding could reduce free luminal iron when the two are dosed together. This has not been measured against an iron salt in people.

The free thiol on N-acetylcysteine reduces ferric to ferrous iron and also forms weak complexes with it. That means it can shift the redox state of luminal iron in either direction depending on concentration. The practical effect on absorption from a ferrous salt has not been characterised.

Coffee lowers non-heme iron absorption when taken at the same meal, but the responsible compounds are chlorogenic acid and other polyphenols rather than caffeine itself. A caffeine-only supplement does not carry that chemistry. The distinction matters because the interaction is routinely mis-attributed to caffeine.